COSMNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends December 31

Cosmos Health Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026

$0.33−0.01 (-1.90%)

Close on Oct 19, 2026

Market cap: $19.48M
P/E (TTM): –
Dividend yield: –

Cosmos Health Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2012 2012-07-31	FY 2011 2011-07-31	FY 2010 2010-07-31
Revenue	65	54	53	50	56	55	40	37	30	6.76	0.53	7.64	–	–	–
Cost of Revenue	57	50	49	44	48	47	36	35	28	6.15	0.48	–	–	–	–
Gross Profit	7.90	4.31	4.35	5.96	8.33	8.06	3.66	2.41	1.96	0.60	0.05	7.64	–	–	–
Research & Development	0.52	0.53	0.16	–	–	–	–	–	–	–	–	–	–	–	–
Selling, General & Admin	16	12	21	11	9.94	2.87	3.52	–	–	–	–	–	–	–	–
Selling & Marketing	0.15	0.35	1.20	0.63	0.73	0.76	0.23	–	–	–	–	–	–	–	–
General & Administrative	16	12	20	10	9.21	2.10	3.29	3.59	4.85	0.79	0.49	0.44	0.33	0.17	–
Operating Expenses	25	20	26	13	13	5.35	3.92	3.64	6.83	0.80	0.49	0.52	–	–	–
Operating Income	-17	-16	-22	-7.47	-4.53	2.71	-0.26	-1.23	-4.87	-0.20	-0.44	7.12	-0.33	-0.17	–
Interest Expense	1.90	1.01	0.87	2.35	2.82	2.76	-1.41	-0.97	0.75	0.19	0.09	0.06	–	–	–
Interest & Investment Income	0.40	0.41	0.66	0.24	0.05	0.07	0	–	–	–	–	–	0	0	–
Other Non-Operating Income	-2.44	-0.64	3.29	-5.58	-3.31	-1.52	-2.86	-7.81	–	–	–	–	–	–	–
Asset Impairment Charges	0.16	0.13	0	–	–	–	–	0	1.95	–	–	–	–	–	–
Gain (Loss) on Investments	0.02	0.00	0.00	0.00	–	–	0.00	2.50	–	–	-6.15	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	0.15	–	–	–	–	–	–	–
Pretax Income	-19	-16	-19	-13	-7.85	1.20	-3.12	-9.04	-6.21	-0.60	-6.69	7.04	–	–	–
Income Tax Expense	0	0	0	-0.78	0.11	-0.38	0.18	-0.02	0.00	0.00	0.00	1.00	–	–	–
Net Income incl. Noncontrolling Interests	-19	-16	-19	-14	-16	0.82	-3.30	-9.06	–	–	–	–	–	–	–
Net Income	-19	-16	-19	-14	-7.96	0.82	-3.30	-9.06	-6.21	-0.60	-6.69	6.04	-0.33	-0.17	-3.79
Preferred Dividends	–	0	0.37	–	–	–	–	–	–	–	–	–	–	–	–
Net Income to Common	-19	-22	-26	-64	-16	0.82	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-0.63	-1.17	-2.15	-33.16	-23.74	1.50	-6.25	-17.00	-12.25	-1.25	-12.50	12.50	-2.50	-2.50	–
EPS (Diluted)(per share)	-0.63	-1.17	-2.15	-33.16	-23.74	1.50	-6.25	-17.00	-12.25	2,018,525.00	-12.50	12.50	-2.50	-2.50	–
Shares Outstanding (Basic, Weighted)(shares)	30	19	12	1.93	0.66	0.53	0.53	0.53	0.51	0.50	0.50	0.50	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	30	19	12	1.93	0.66	0.53	0.53	0.53	0.51	0.50	0.50	0.50	–	–	–
EBITDA	-15	-14	-21	-7.29	-4.18	3.11	0.14	-1.18	–	–	–	–	–	–	–
Net Interest Income	–	–	–	–	–	–	–	–	–	–	0.00	0.00	–	–	–
Non-Interest Expense	–	–	–	0.22	–	0.03	0.32	-5.84	0.89	0.02	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 10.3%
Operating margin: -24.9%
Net margin: -33.1%
Return on equity, FY2025: -89.1%

Financial strength

Current ratio: 1.05
Debt to equity: 0.06
Debt to assets: 1.9%
Cash to current liabilities: 5.2%

Valuation

P/E ratio: –
Price to sales: 0.26
Price to book: 0.94
Dividend yield: –